- 1 Clinical evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid,
- fluoroquinolone, ethionamide and second-line drug resistance: A cross-sectional 2
- 3 multicentre diagnostic accuracy study
- 5 **Authors:**

11

- Adam Penn-Nicholson, PhD; 1* Sophia B. Georghiou, PhD; 1* Nelly Ciobanu, MD; 2, Mubin 6
- Kazi, PhD;³ Manpreet Bhalla, MD;⁴ Anura David, MSc;⁵ Francesca Conradie, MBBCh;⁵ Morten 7
- Ruhwald, MD; ¹ Valeriu Crudu, MD; ² Camilla Rodrigues, MD; ³ Vithal Prasad Myneedu, MD; ⁴ 8
- Lesley Scott, PhD;⁵ Claudia M Denkinger, MD;^{1,6} Samuel G Schumacher, PhD;¹ Xpert XDR 9
- 10 Trial Consortium**
- ¹ Foundation for Innovative New Diagnostics, Campus Biotech, 9 Chemin des Mines 12
- 13 1202 Geneva, Switzerland
- ² Institute of Phthisiopneumology "Chiril Draganiuc", 13, C. Virnav street 14
- 15 MD 2025, Chisinau, the Republic of Moldova
- ³ P.D. Hinduja Hospital and Medical Research Centre, SVS Rd, Mahim West, Shivaji Park 16
- 17 Mumbai, Maharashtra 400016, India
- ⁴ National Institute of TB and Respiratory Diseases, Sri Aurobindo Marg Near Qutub Minar, 18
- 19 Mehrauli, New Delhi, Delhi 110030, India
- ⁵ University of the Witwatersrand, School of Pathology, York Road, Parktown, Johannesburg, 20
- 21 2193, South Africa
- ⁶ Heidelberg University Hospital, Center of Infectious Diseases, Im Neuenheimer Feld 324, 22
- 23 69120 and German Center of Infection Research, Site Heidelberg, Heidelberg, Germany

24 *Authors contributed equally 25 **The members of the Xpert XDR Trial Consortium are listed at the end of this paper. 26 **Corresponding author:** 27 28 Adam Penn-Nicholson 29 adam.penn-nicholson@finddx.org +41 (22) 710 05 91 30 31

Campus Biotech, 9 Chemin des Mines

1202 Geneva, Switzerland

32

33

34

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Abstract: Background The WHO End TB Strategy requires universal drug susceptibility testing and treatment of all people with tuberculosis. However, available second-line diagnostic tools are cumbersome and require sophisticated laboratory infrastructure, and ultimately less than half of those with drugresistant tuberculosis receive appropriate treatment. Xpert MTB/XDR was developed to help overcome these limitations. Methods We assessed the diagnostic accuracy of sputum-based Xpert MTB/XDR for isoniazid, fluoroquinolone, ethionamide and second-line injectable resistance detection in adults with an Xpert MTB/RIF or Ultra Mycobacterium tuberculosis-positive result against a composite reference standard of phenotypic drug-susceptibility testing and whole genome sequencing (NCT03728725). Participants with pulmonary tuberculosis symptoms and ≥ 1 risk factor for drug resistance were consecutively enrolled between four clinical sites in India, Moldova and South Africa. *Findings* Between 31 July 2019 and 21 March 2020, we enrolled 710 patients, of which 611 (86.1%) had results from index and composite reference standard tests and were included in analysis. The sensitivity of Xpert MTB/XDR was 94% for isoniazid, 95% for fluoroquinolones, 54% for ethionamide, 73% for amikacin, 86% for kanamycin, and 61% for capreomycin resistance

detection. Specificity was 98-100% for all drugs. Performance was equivalent to line-probe assays. The non-determinate rate of Xpert MTB/XDR was 2-96%.

Interpretation

This first prospective, multicentre clinical study of the Xpert MTB/XDR assay demonstrated high diagnostic test accuracy, meeting target product profile criteria for a next-generation drug susceptibility test.

Funding

German Federal Ministry of Education and Research through KfW, Dutch Ministry of Foreign Affairs, and Australian Department of Foreign Affairs and Trade.

Research in context:

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Evidence before this study The World Health Organization (WHO) has highlighted the development of expanded, rapid molecular drug susceptibility tests as a key priority to tackle drug-resistant tuberculosis (TB). Prior to the Cepheid Xpert MTB/XDR assay, the only WHO-recommended rapid molecular assay for second-line resistance detection was the Bruker-Hain GenoType MTBDRsl line probe assay. However, the high complexity of DNA-based hybridization assays limits their use to central reference or regional-level laboratories where the appropriate infrastructure and user expertise can be ensured. In this context, the Xpert MTB/XDR assay is the only lower complexity, automated molecular assay for broader resistance detection suitable for use at lower levels of the laboratory network. We searched PubMed databases for articles evaluating the performance of the sputum-based assay using search terms (tuberculosis or TB) AND (Xpert OR GeneXpert OR cartridge) AND (second-line OR XDR OR "extensively drug-resistant") AND (sputum OR sputa) AND (test OR assay OR diagnostic OR "point of care") AND (performance OR accuracy OR sensitivity OR specificity OR diagnos*). The search was done on 8 Feb 2021 with no search date or language restrictions. Our search yielded 51 studies, of which only three reported on a sputum-based cartridge for expanded resistance detection. The first two studies described the assay design approach and reported initial performance metrics for a prototype version of the Xpert MTB/XDR assay. In the third study, the manufacturer demonstrated high performance for the final assay (sensitivity of 94–100% and a specificity of 100% for all drugs except for ethionamide) when compared with sequencing for 314 sputum specimens and

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

sediments. This study was the first assessment of Xpert MTB/XDR assay diagnostic accuracy in a prospective patient cohort. Added value of this study This is the first clinical study of the diagnostic performance of the Xpert MTB/XDR assay for expanded drug resistance detection. This study was performed independent of the manufacturer in settings of intended use utilizing prospectively collected primary clinical samples. The study employed a comprehensive reference standard using both phenotypic drug susceptibility testing and whole genome sequencing separately, as well as in combination, which allowed a differentiated view of performance of the assay for resistance detection. Moreover, we compared the performance of the assay on direct sputum samples with the performance of the WHOrecommended Bruker-Hain MTBDR*plus* and MTBDR*sl* line probe assays on culture. *Implications of all the available evidence* The WHO End TB Strategy calls for early diagnosis and universal access to drug susceptibility testing. With a 10-color calibration to GeneXpert instruments, the Xpert MTB/XDR assay expands upon the drug detection landscape of the Xpert MTB/RIF and Ultra assays and overcomes the limitations of the Bruker-Hain line probe assays to offer an option for lower-level health care centres to conduct rapid, expanded drug susceptibility testing in follow-up to a TBpositive result using existing laboratory infrastructure. Data from this study demonstrates that the Xpert MTB/XDR assay has high performance for a diverse clinical population in the intended setting of use, providing national TB programmes with a valuable tool for expanded drug susceptibility testing for all persons with signs and symptoms of TB.

Background:

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

In 2010, the World Health Organization (WHO) recommended the use of the Xpert MTB/RIF® assay ("Xpert", Cepheid, Sunnyvale, CA), an integrated, automated, cartridge-based system for multidrug-resistant tuberculosis (MDR-TB) diagnosis that uses the GeneXpert instrument platform. The assay and its more sensitive WHO-recommended successor, Xpert MTB/RIF Ultra® ("Ultra"), have since been widely adopted in tuberculosis (TB) programmes.² Both assays identify Mycobacterium tuberculosis if present in the specimen. However, both assays detect rifampicin (RIF) resistance only, and thus do not provide sufficient information regarding a given strain's resistance profile necessary to diagnose M. tuberculosis resistance to additional drug compounds, including the first-line drug isoniazid (INH), fluoroquinolones (FQ) and any of the injectable compounds [amikacin (AMK), kanamycin (KAN) and/or capreomycin (CAP)]. The rapid diagnosis and appropriate treatment of drug-resistant TB (DR-TB) is essential to prevent significant morbidity, mortality and further transmission of TB disease. Given the importance of INH and the FQs, in particular, in current TB and DR-TB patient treatment regimens.³⁻⁶ it is critical to rule-out resistance to these compounds prior to treatment. The novel Xpert MTB/XDR assay is a rapid, sputum-based assay that is indicated for use as a reflex test to any M. tuberculosis positive result to test for resistance to INH, FO, ethionamide (ETH), and second-line injectable drugs (SLI). A prototype version of the assay showed promising performance for INH and second-line resistance detection in a blinded study of 24 clinical sputum samples (sensitivity 75–100%; specificity 94–100%), as well as in a clinical evaluation study (sensitivity 92·7–98·1%; specificity 94·3–99·6%). 8,9 The assay has since been updated with additional gene targets and the time-to-result shortened to 90 minutes. The final

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

assay detects INH resistance-associated mutations in katG, the inhA promoter, fabG1 and the oxyR-ahpC intergenic gene region, FQ resistance-associated mutations in gyrA and gyrB, ETH resistance-associated mutations in the *inhA* promoter, and SLI (AMK, KAN and CAP) resistance-associated mutations in rrs and the eis promoter. In a retrospective study of 314 clinical sputum samples and sediments in two laboratories, the final assay demonstrated high performance compared with sequencing (99.7%, 97.5%, 100%, 96.5%, 94.1% and 88.5% for detection of INH, FLO, AMK, KAN, CAP and ETH resistance respectively, with a specificity of 100% for all the drugs except for ETH, for which the assay demonstrated a specificity of 97.3%). 10 We conducted a cross-sectional, multicentre, diagnostic accuracy study in which the performance of the Xpert MTB/XDR assay on sputum samples was assessed in four reference laboratories in settings of intended use against Mycobacteria Growth Indicator Tube (MGIT) culture phenotypic drug susceptibility testing (pDST) and whole genome sequencing (WGS) as a composite reference standard for the diagnosis of INH, FQ, ETH, AMK, KAN and CAP resistance. **Methods:** Study design and participants This prospective, multicentre, cross-sectional diagnostic accuracy study (NCT03728725) was sponsored by FIND and conducted with the Phthisiopneumology Institute "Chiril Draganiuc", in Chisinau, Moldova, P.D. Hinduja Hospital and Medical Research Centre in Mumbai, India, the National Institute of TB and Respiratory Diseases (NITRD) in New Delhi, India, and University

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

of the Witwatersrand in Johannesburg, South Africa. The study was conducted in accordance with the 1964 Helsinki declaration and later amendments and approved by the relevant institutional review boards and independent ethics committees. All participants provided informed consent. Individuals were recruited at outpatient clinic settings and inpatient hospital settings. Interested individuals were referred to study personnel for additional information and screening. Screening criteria included age 18 years or above, symptoms suggesting pulmonary tuberculosis and at least one risk factor for DR-TB. Participants were consecutively enrolled in the study if they met inclusion criteria, provided informed consent, had a M. tuberculosis-positive Xpert or Ultra result with either a RIF-resistant or -sensitive result, and provided at least 3 mL of sputum. Information regarding patient sex, age, weight, height, infection site, previous TB treatment start date and drug regimen, pulmonary symptoms, and HIV status were collected at enrolment. Clinical information and reference test result were not available to operators or readers of the index test at the time of data generation. All data entry was validated with source document verification. Xpert MTB/XDR test results were not shared with clinical staff and did not influence patient treatment options. The full study protocol is provided as Supplement S1, and at clinicaltrials.gov (NCT03728725). **Procedures** Patients meeting eligibility criteria were asked to provide ≥3 mL of sputum as either a single sputum or two consecutively collected and pooled sputa. Samples were homogenized with glass

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

beads and split for testing. Xpert MTB/XDR and acid-fast bacilli smear were performed directly on the homogenized sputum sample. Liquid (MGIT) and solid (LJ) culture were performed using 2 mL of decontaminated sputum. MGIT DST was performed for all culture-positive samples for INH, RIF, FQs (moxifloxacin and levofloxacin), ETH, AMK, KAN, and CAP at the WHOrecommended critical concentrations for MGIT DST. 11,12 Cultured samples underwent subsequent testing by Bruker-Hain GenoType MTBDRplus, MTBDRsl LPA, and WGS to report high-confidence resistance mutations in relevant gene regions (katG, inhA, fabG1, ahpC, gyrA, gvrB, rrs, eis, and tlvA), 13 as well as a second Xpert MTB/XDR assay. DNA for WGS was extracted on site from 300 µL positive MGIT culture using Molzym Ultra-Deep Microbiome Prep kits and extracts were sent to MedGenome (Bangalore, India) for WGS (Supplement S2). Statistical analysis We estimated that 760 total samples would need to be tested for this study to yield 600 specimens with full results (accounting for around 20% of culture and molecular tests with invalid and indeterminate results). We estimated that the analysis of 600 specimens would allow us to assess INH, FQ, AMK, KAN, and CAP sensitivity with 95% confidence intervals (based on the Wilson score method), of 7%, 13%, 23%, 16%, and 23%, respectively, and specificity with 95% confidence intervals of 3–4%, based upon knowledge of past drug resistance rates for the given sites or regions. ¹⁴ More detail on the sample size calculations is provided in the protocol (Supplement S1). Primary analyses focused on estimating accuracy (clinical sensitivity and specificity) for INH, ETH, FQ (moxifloxacin or levofloxacin), AMK, KAN, and CAP resistance detection using a

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

composite reference standard. Specimens were labelled as drug-resistant if either pDST or WGS suggested drug-resistance; specimens were labelled as drug-sensitive if both pDST and WGS suggested drug-sensitivity. For each drug, clinical sensitivity was defined as the proportion resistant based on the composite reference standard that tested resistant by Xpert MTB/XDR. Clinical specificity was defined as the proportion susceptible based on the composite reference standard that tested susceptible by Xpert MTB/XDR. For simple proportions (sensitivity and specificity), 95% confidence intervals were computed using the Wilson score method. Primary diagnostic accuracy analyses were carried out across all study sites. All TB samples that generated both Xpert MTB/XDR (resistant or susceptible) and composite reference standard results contributed to the analysis of the diagnostic test accuracy for INH, FQ, ETH, and SLI resistance detection. Non-determinate rates of the Xpert MTB/XDR assay, defined as invalid M. tuberculosis detection, as well as indeterminate rates, defined as indeterminate results for drug resistance among valid M. tuberculosis detection results, were also calculated across study sites as a percentage of all Xpert MTB/XDR tests performed on patient sputa. Secondary analyses investigated assay diagnostic accuracy between important subgroups, including: Xpert MTB/XDR performance on direct sputum ("on sputum") versus cultured isolates ("on isolates"), performance by smear result, performance between clinical sites, performance by patient HIV status and TB pre-treatment status, and performance compared with the Bruker-Hain MTBDR*plus* and MTBDR*sl* assays. Detailed definitions for diagnostic test results are given in Supplement S3.

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

Role of the funding source The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. **Results:** Between 31 July 2019 and 21 March 2020, 714 patients were screened for eligibility (Figure 1). A total of 710 patients were enrolled, of whom 99 were excluded, mainly as a result of negative cultures for M. tuberculosis (n=89) and the remaining 10 for missing or invalid reference or index test results. The initial population of 710 participants had a smear positivity rate of 69% and a culture positivity rate of 87%. The final, analysed population of 611 participants, for which results from both Xpert MTB/XDR and reference standard were available, had a median age of 37 years (18–77). Of these participants, 35% were women and 16% were HIV-positive (Figure 1, Table 1); 81% were Xpert MTB/RIF or Ultra RIF-resistant, while 76% were smear-positive for M. tuberculosis. The Xpert MTB/XDR assay had high diagnostic accuracy for the detection of INH, FQ, AMK, KAN, and CAP resistance in the clinical study (Figure 2). For Xpert MTB/XDR performed directly on sputum, sensitivity and specificity were 94% and 100% for INH resistance detection, 94% and 99% for FQ resistance detection, 54% and 100% for ETH resistance detection, 73% and 100% for AMK resistance detection, 86% and 98% for KAN resistance detection, and 61% and 100% for CAP resistance detection compared with a composite reference standard of pDST and WGS.

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

There was no notable difference of Xpert MTB/XDR performance when using sputum compared with isolates for the assay sample (Supplement S3). Xpert MTB/XDR invalid rate (i.e. unsuccessful test) was notably higher for smear negative samples than for smear positive samples (6.2% compared with 0.2%), though we detected no notable differences in performance for drug resistance detection based upon smear status (S3). Additionally, there were no performance differences by patient HIV or pre-treatment status (S3). There were a few notable Xpert MTB/XDR performance differences by site (Figure 3). The sensitivity of the assay for INH resistance detection was lower in New Delhi (80%; 95% CI 70– 88%) than other sites, with WGS revealing the presence of INH resistance mutations that are not included in the Xpert MTB/XDR assay (e.g. katG W135* stop codon), though specificity was high (100%) across all sites. Likewise, the sensitivity of the assay for ETH resistance detection was low in New Delhi and Mumbai compared with Moldova and South Africa, though specificity was high across and between sites. For SLI resistance detection, the Xpert MTB/XDR assay sensitivity was also notably lower in New Delhi (26–33%) than for other sites. The sensitivity of the assay for CAP resistance detection was also notably low in Moldova (40%). However, it should be noted that the sensitivity estimates for Xpert MTB/XDR detection of SLI resistance detection in New Delhi and CAP resistance detection in Moldova greatly improved if only pDST was used as a reference standard (67–75% and 56%, respectively, see Supplement S3).

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

The overall non-determinate rate for the Xpert MTB/XDR assay was 2.96% (Table 2). Drug resistance indeterminate rates, among valid Xpert MTB/XDR M. tuberculosis-detected results, were <3.5% for all drugs included in the assay. The Xpert MTB/XDR assay performed similarly to the Bruker-Hain line probe assays (LPAs) for INH, FQ, AMK, KAN, and CAP resistance detection, even though the Xpert MTB/XDR assay was performed directly on sputum samples while the LPAs were performed only on cultured samples (Table 3). The only difference was for INH resistance detection, as the Xpert MTB/XDR assay demonstrated slightly higher sensitivity, likely attributed to the two additional gene targets in Xpert MTB/XDR that are not found in the MTBDRplus assay (i.e. fabG1 and the ahpC-oxyR intergenic region). Of the eight samples that were Xpert MTB/XDR INH-resistant, but MTBDR*plus* INH-susceptible in this study, WGS confirmed that two had *ahpC-oxyR* mutations (i.e. c-10t and c-15t) and three had the fabG1 L203L mutation in the absence of other mutations. Two of the 8 samples did not have WGS available, though WGS confirmed that the 8th sample had a katG S315T mutation that was not detected by the LPA. **Discussion**: This is the first prospective, clinical diagnostic accuracy study of the Xpert MTB/XDR assay for INH, FQ, ETH, and second-line TB drug resistance detection. We found that the Xpert MTB/XDR assay, performed directly on smear-positive and smear-negative sputum specimens, demonstrated high diagnostic accuracy for the detection of INH, FQ, AMK, KAN, and CAP resistance among patients from the three WHO regions of Africa, Europe, and South-East Asia.

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

Importantly, direct Xpert MTB/XDR testing of sputum samples produced results for resistance on all drugs in 96% of tested *M. tuberculosis*-positive specimens with a single, easy-to-use assay. The assay demonstrated slightly better performance for INH resistance detection compared with the Bruker-Hain MTBDR*plus* assay (1.6%, 95% CI 0.2-3.4), as the assay includes two additional gene targets not found in the LPA (i.e. fabG1 and the ahpC-oxyR intergenic region), and equivalent performance for second-line resistance detection compared with the Bruker-Hain MTBDRsl assay. Notably, specificity was high (>98%) for the detection of all drugs included in the Xpert MTB/XDR assay. Sensitivity of the assay varied by drug target, ranging from 54% for ETH resistance detection to 94% for FQ resistance detection against the composite reference standard. For INH, FQ, and SLI resistance detection, performance estimates met minimal criteria of the WHO target product profile for a next-generation DST assay to be used at peripheral microscopy centres compared with pDST (no criteria have been defined to date for ETH or for a composite reference standard). 15 Furthermore, no performance differences were seen by smear status or patient HIV or pre-treatment status, highlighting the suitability of the test for a diverse patient population. Some notable diagnostic performance variations were identified by site. In particular, assay sensitivity for INH resistance detection was lower in New Delhi (80%, 95% CI 70–88%) than for other sites. Most of the Xpert MTB/XDR INH false-negative samples in New Delhi were phenotypically INH-resistant with no high confidence resistance mutation(s) in the gene regions covered by the Xpert MTB/XDR assay. For example, three phenotypically INH-resistant

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

samples from NITRD had *ahpC* t-34a/g mutations that are outside of the coverage of the Xpert MTB/XDR assay. Additionally, two different Indian isolates had stop codons in katG (W135* and E607*) that were not identified by the Xpert MTB/XDR assay. Importantly, the MTBDRplus LPA also did not identify INH resistance for any of these samples, further suggesting that INH resistance mechanisms outside of those covered by the Xpert MTB/XDR assay and most other current molecular assays might play a role in resistance in this geographical context. Assay sensitivity for ETH resistance detection, in contrast, was low both overall and between sites, likely due to the fact that the Xpert MTB/XDR assay is only capable of detecting ETH resistance-associated mutations in one gene region (i.e. the *inhA* promoter), and so other phenotypic ETH resistance mechanisms, such as *ethA* resistance mutations, ¹⁶ were missed by Xpert MTB/XDR, since they are not targeted by the assay. As no graded list of ethA resistance mutations currently exists for ETH, and ETH pDST is unreliable, ¹⁷ we are unable to comment upon potential improvements in diagnostic performance if ethA resistance mutations were included in the assay. The low sensitivity for ETH suggests a role of the assay for ruling-in but not for ruling-out resistance to ETH. For SLI resistance detection, Xpert MTB/XDR sensitivity was notably lower in New Delhi (26– 33%, depending on the drug) than for the other sites. Upon closer examination, it was determined that 11 of the 14 false-negative results in New Delhi were from specimens that were phenotypically SLI-susceptible but heteroresistant by WGS, with rrs c1402a and g1484t mutations present in only a fraction of WGS reads at levels likely undetectable by the Xpert MTB/XDR assay (the rrs c1402a mutation was detected in <50% of reads for nine of the 11 samples). 10,18 Ultimately, the clinical relevance of these minor resistant populations is unclear

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

given that these samples were phenotypically SLI-susceptible. If only pDST was considered as a reference standard in this study, the sensitivity of the Xpert MTB/XDR assay would improve to 67–75% for the detection of SLI resistance in New Delhi and 75–92% overall. The sensitivity of the assay for CAP resistance detection was also low in Moldova (40%, 95% CI 22–61%), likely due to the fact that certain CAP resistance mutations were present in only a low fraction of generated WGS reads for Xpert MTB/XDR false-negative samples (e.g. the rrs c1402a mutation was detected in <25% of reads for the five CAP-resistant samples that were not detected by Xpert MTB/XDR). Furthermore, a few additional phenotypically CAP-resistant samples did not have any resistance mechanisms detected by WGS, including tlyA mutations, suggesting that additional resistance mechanisms outside of those covered by the Xpert MTB/XDR assay might play a role in CAP resistance in Moldova.¹⁹ The strengths of this study included the enrolment of patients in four diverse sites in three WHO regions, the use of WHO-recommended molecular comparators (Bruker-Hain GenoType MTBDR*plus* and MTBDR*sl*), and the use of a composite reference standard to fully characterize assay performance. To investigate the performance of Xpert MTB/XDR in real-world populations, an effort was made to include diverse clinical populations across different geographical regions widely representative of the TB epidemic. However, differences in local patient populations, laboratories, and M. tuberculosis strains may have also contributed to performance variations seen between sites and reflect a limitation of studies including diverse populations. It is important to note that the study did not allow for evaluation of Xpert MTB/XDR assay performance for TB detection. As the study was designed to assess the Xpert MTB/XDR assay as a reflex test to any TB positive result, only Xpert MTB/RIF and Ultra M.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

tuberculosis-positive patients were enrolled in our study, and so no data were available to confirm Xpert MTB/XDR specificity for TB detection. Although previous studies have demonstrated the limit of detection of the Xpert MTB/XDR assay to be equivalent to Xpert MTB/RIF, 10,18 additional prospective, clinical data would be helpful to support this finding and define best use cases. Furthermore, the study was designed to evaluate a high number of drugresistant specimens to provide accurate sensitivity estimates, and this was achieved by testing mostly RIF resistant samples, but also meant that sample size was relatively low to assess Xpert MTB/XDR specificity for INH resistance detection. However, given that no false positive results were obtained in this study, overall confidence is high in the specificity of the assay for INH resistance detection. As a reflex test to an Xpert MTB/RIF or Ultra TB-positive result, the Xpert MTB/XDR assay allows for rapid extended drug resistance profiling directly from sputum, using existing infrastructure and sample processing procedures, thereby providing a decentralized option for optimized TB treatment. Given the importance of INH in TB treatment regimens, ³⁻⁶ as well as the growing concerns regarding INH mono-resistant strains of TB. 20 the availability of a sputumbased assay with an expanded landscape for INH resistance detection may be of great value to best direct appropriate TB patient treatment in many contexts. Although the definition of XDR-TB was redefined by WHO in 2021, the assay still presents a crucial diagnostic to identify and direct treatment of INH-resistant TB, FQ-resistant TB, and pre-XDR TB, now defined as M. tuberculosis strains that fulfil the definition of multidrug-resistant/rifampicin-resistant TB and which are also resistant to any FQ.²¹ The relevance of the assay is underscored given the importance of INH and FQ in current drug-susceptible and drug-resistant treatment regimens, ³⁻⁶

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

and the assay fills the need for rapid FQ DST to all-oral, short course drug-resistant TB regimens. While the importance of determining resistance to SLIs has decreased given changing TB treatment guidelines, there is still value in having this information as SLIs remain in widespread use as countries make the switch to all-oral regimens, as well as for patients who fail on these novel regimens. Additional field studies will be necessary to determine the optimal placement of the assay in existing diagnostic and laboratory algorithms and the acceptability and robustness of the GeneXpert instruments with 10-color calibration needed to perform the assay, especially in high burden countries with varying infrastructure capacities.²² Overall, the Xpert MTB/XDR assay met the minimal criteria set by the WHO target product profile for a next-generation DST, although sensitivity of the assay for ETH resistance detection was low and performance variations were identified between sites. 15,23 The introduction and rollout of this rapid sputum-based assay has the potential to greatly improve TB patient diagnosis and management worldwide. Additional studies, including demonstration studies of various implementation approaches, will be critical to define best use cases for the Xpert MTB/XDR assay and ensure optimal impact in improving outcomes for patients with drug-resistant TB.

References: Cepheid. Xpert MTB/RIF Package Insert. 2019. http://www.cepheid.com/us/mtbrif-pi. WHO. Global TB Report 2019. Geneva, Switzerland, 2019 https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_12Nov2019.pdf?ua=1 WHO. Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis. 2019 https://www.who.int/tb/publications/2019/rapid communications MDR/en/. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017) update). 2017 https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/. WHO. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland, 2018. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. Xpert MTB-XDR ENGLISH Package Insert 302-3514 Rev A. . Chakravorty S, Roh SS, Glass J, et al. Detection of isoniazid-, fluoroquinolone-, amikacin-, and kanamycin-resistant tuberculosis in an automated, multiplexed 10-color assay suitable for point-of-care use. J Clin Microbiol 2017; **55**: 183–98. Xie YL, Chakravorty S, Armstrong DT, et al. Evaluation of a rapid molecular drugsusceptibility test for tuberculosis. N Engl J Med 2017; **377**: 1043–54. Cao Y, Parmar H, Guar R, et al. Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. J Clin *Microbiol* 2021; **59**: e02314-20.

433 11 WHO. Technical report on critical concentrations for TB drug susceptibility testing of 434 medicines used in the treatment of drug-resistant TB. 2018 435 https://www.who.int/tb/publications/2018/WHO technical report concentrations TB dru 436 g susceptibility/en/. 437 WHO. Technical report on critical concentrations for TB drug susceptibility testing of 12 438 medicines used in the treatment of TB. 2020. 439 13 Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the 440 association between mutations and phenotypic drug resistance in Mycobacterium 441 tuberculosis. Eur Respir J 2017; **50**: 1701354. 442 14 Catanzaro A, Rodwell TC, Catanzaro DG, et al. Performance comparison of three rapid 443 tests for the diagnosis of drug-resistant tuberculosis. *PLoS One* 2015; **10**: 1–14. 444 15 WHO Report M. Global TB Programme Meeting Report: High-priority target product 445 profiles for new tuberculosis diagnostics: Report of a consensus meeting. Geneva, 446 Switzerland, 2014 DOI:WHO/HTM/TB/2014.18. 447 16 Vilchèze C, Jacobs JR. WR. Resistance to isoniazid and ethionamide in Mycobacterium 448 tuberculosis: Genes, mutations, and causalities. *Microbiol Spectr* 2014; 2: MGM2-0014– 449 02913. 450 17 Theresa E, Werngren J, Groenheit R, et al. Systematic review of whole genome 451 sequencing data to predict phenotypic drug resistance susceptibility in Swedish 452 Mycobacterium tuberculosis isolates 2016-2018. Antimicrob Agents Chemother 2020; 64: 453 e02550-19. 454 Georghiou SB, Penn-Nicholson A, de Vos M, et al. Analytical performance of the Xpert 18 455 MTB/XDR® assay for tuberculosis and expanded resistance detection. *Diagn Microbiol*

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

Infect Dis 2021; in press. 19 Georghiou SB, Seifert M, Catanzaro D, et al. Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother 2016; 60: 3994–4004. 20 Karo B, Kohlenberg A, Hollo V, et al. Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: Analysis of European surveillance data, 2002 to 2014. Eurosurveillance 2019. DOI:10.2807/1560-7917.ES.2019.24.12.1800392. 21 WHO. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. Geneva, Switzerland, 2021. 22 Bainomugisa A, Gilpin C, Coulter C, Marais BJ. New Xpert MTB/XDR: added value and future in the field. Eur Respir J 2020; **56**. DOI:10.1183/13993003.03616-2020. Denkinger CM, Dolinger D, Schito M, et al. Target product profile of a molecular drug-23 susceptibility test for use in microscopy centers. J Infect Dis 2015. DOI:10.1093/infdis/jiu682. 24 Dravid A, Natarajan K, Medisetty M, et al. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India. *BMC Infect Dis* 2019. DOI:10.1186/s12879-019-4361-0. **Data sharing statement** Individual, de-identified participant data will be shared, including data dictionaries. Other documents that have been made available include the study protocol and statistical analysis plan. Templates of the informed consent forms may be shared upon request. The data will be available immediately following publication with no end date. The data will be shared with anyone who

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

wishes to access the data. The data will be available for any purpose of analyses. For data, please contact the corresponding author. **Xpert XDR Trial Consortium members** Catharina Boehme, Sergio Carmona, Sarabjit Chadha, Megha Dhalla, Christine Hoogland, Aurélien Macé, Shweta Mall, Stefano Ongarello, Shakir Reza, Sanjay Sarin, Shubhada Shenai (Foundation for Innovative New Diagnostics, Geneva, Switzerland); Trish Kahamba, Wendy Stevens, Lyndel Singh, Xabisa Makeleni (University of the Witwatersrand, Johannesburg, South Africa); Ritu Singhal; Jyoti Arora; Rohit Sarin (National Institute of TB and Respiratory Diseases, New Delhi, India). **Acknowledgements** The authors would like to thank the study participants and their families for generously volunteering to participate in this study, as well as the study sites for their time and effort in conducting the study, and assisting with the analysis of the operational data. The authors also thank ACOMED for conduction statistical analysis, MedGenome for WGS and Cepheid for their technical expertise towards the study. Medical writing support was provided by Talya Underwood, MPhil, of Anthos Communications Ltd, UK, funded by the Foundation for Innovative New Diagnostics, according to Good Publication Practice guidelines. **Contributors** APN, SBG, CMD, and SGS designed the study; APN, SBG, MR, LS, VPM, CR, VC, CMD, SGS oversaw the study. NC, MK, MB, AD, and FC coordinated the individual study sites.

sector companies.

Statistical analysis was undertaken by ACOMED. The manuscript drafts were developed by SBG, APN, CMD, and SGS with input from the authors. All authors contributed to interpretation of data and editing of the article and approved the final version of the manuscript.

Declaration of interests

APN, CMD, MR, SBG, and SGS are employed by the Foundation for Innovative New Diagnostics (FIND). FIND is a not-for-profit foundation that supports the evaluation of publicly prioritized tuberculosis assays and the implementation of WHO-approved (guidance and prequalification) assays using donor grants. FIND has product evaluation agreements with several private sector companies that design diagnostics for tuberculosis and other diseases. These agreements strictly define FIND's independence and neutrality with regard to these private

Tables

514

515

516

Table 1. Demographics and clinical characteristics of analysed patient cohort.

	India - Mumbai:	India - NITRD:	Moldova - PPI:	South Africa -	Total - All
	Hinduja	New Delhi	Chisinau	WHC:	participants
				Johannesburg	
N [%]	179 [29%]	120 [20%]	230 [38%]	82 [13%]	611 [100%]
Demographics or clinical characterist	stics				
Median age [min - max] (years)	31 [18, 77]	30 [18, 72]	43 [18, 70]	36 [18, 64]	37 [18, 77]
% Female sex [n/N]	49% [88/179]	43% [52/120]	20% [45/230]	35% [29/82]	35% [214/611]
% HIV positive [n/N]	2% [1/41]*	0% [0/107]	12% [27/230]	87% [41/47]	16% [69/425]
% Xpert MTB/RIF or Ultra RIF-R	82% [146/179]	63% [75/120]	92% [212/230]	74% [61/82]	81% [494/611]
[n/N]					
Distribution in diagnostic categories					
% Smear-negative culture-positive	24% [42/179]	41% [49/119]	17% [39/230]	20% [16/81]	24% [146/609]
[n/N]					
% INH-R based upon composite	84% [146/174]	73% [85/116]	94% [217/230]	88% [51/58]	86% [499/578]
reference standard [n/N]					
% ETH-R based upon composite	62% [106/170]	29% [32/110]	72% [165/228]	71% [31/44]	61% [334/552]
reference standard [n/N]					
% FQ-R based upon composite	69% [116/169]	46% [52/113]	25% [56/227]	45% [17/38]	44% [241/547]
reference standard [n/N]					
% AMK-R based upon composite	15% [25/163]	18% [20/109]	10% [22/226]	55% [22/40]	17% [89/538]
reference standard [n/N]					
% KAN-R based upon composite	26% [43/163]	19% [21/110]	59% [135/228]	58% [23/40]	41% [222/541]
reference standard [n/N]					
% CAP-R based upon composite	17% [27/163]	17% [19/109]	11% [25/226]	55% [22/40]	17% [93/538]
reference standard [n/N]					

AMK-R: amikacin-resistant; CAP-R: capreomycin-resistant; ETH-R: ethionamide-resistant; FQ-R: fluoroquinolone-resistant; HIV: human

immunodeficiency virus; INH-R: isoniazid-resistant; KAN-R: kanamycin-resistant; N: total number; NITRD: National Institute of TB and

Respiratory Diseases; RIF-R: rifampicin-resistant; PPI: Phthisiopneumology Institute; WHC: Wits Health Consortium.

* HIV results were available for <50% of patients in Hinduja Hospital. The estimated HIV prevalence among TB-positive patients in Western

521 India is 5%.²⁴

518

520

Table 2. Overall Xpert MTB/XDR non-determinate indeterminate rates from testing of

unprocessed sputum.

resistance was evaluated).

	(%)	n/N	
Non-determinate (MTB invalid)*	2.96	21/709	
Indeterminate (drug resistance) [†]			
INH resistance	0.30	2/657	
ETH resistance	0.15	1/657	
FQ resistance	1.37	9/657	
AMK resistance	3.50	23/657	
KAN resistance	3.20	21/657	
CAP resistance	2.89	19/657	

AMK: amikacin; CAP: capreomycin; ETH: ethionamide; FQ: fluoroquinolones; INH: isoniazid; KAN: kanamycin; MTB: *Mycobacterium tuberculosis*; N: number.

*Non-determinate cases were those with "Invalid" MTB detection results. MTB detection is based upon detection of *inhA* promoter sequence. Of the 710 patients enrolled in the study, one patient did not have Xpert MTB/XDR performed on sputum (i.e. only culture).

† Indeterminant cases were those with "Indeterminate drug resistance" test results among those who had a documented respective "valid Xpert MTB/XDR result with MTB=detected" (drug resistance is only evaluated for specimens where MTB has been detected by the Xpert MTB/XDR assay; 709–21=688 patients had a valid Xpert MTB/XDR result and in 657/688 MTB was detected by the Xpert MTB/XDR assay and thus drug-

Note: 96% (628/657) of sputum samples returned resistance calls for all drugs included in the assay. 18 repeats were conducted for initial non-determinate (invalid test result) samples. Of these 18 samples, only one showed any indeterminate results for any drug (1/18 or 5.56% of repeat tests was AMK, KAN, and CAP resistance-indeterminate).

Table 3. Xpert MTB/XDR performance on sputum compared with MTBDRplus and

MTBDRs1 from culture isolates.

536

537

	N*	TP	FP	FN	TN	Sensitivity % (95% CI)	Specificity % (95% CI)
INH-R detection							
MTBDRplus	575	461	0	36	78	93 (90 to 95)	100 (94 to 100)
Xpert MTB/XDR	575	469	0	28	78	94 (92 to 96)	100 (94 to 100)
Diff. [Xpert MTB/XDR - MTBDRplus]	575					+1.6 (+0.2, +3.4)	0.0 (-4.7, +4.7)
FQ-R detection						I	
MTBDRsl	532	222	2	13	295	95 (91, 97)	99 (97, 100)
Xpert MTB/XDR	532	222	2	13	295	95 (91, 97)	99 (97, 100)
Diff. [Xpert MTB/XDR - MTBDRplus]	532					0.0 (-1.6, +1.6)	0.0 (-1.3, +1.3)
AMK-R detection							
MTBDRsl	511	60	2	22	427	73 (62 to 82)	100 (98 to 100)
Xpert MTB/XDR	511	60	2	22	427	73 (62 to 82)	100 (98 to 100)
Diff. [Xpert MTB/XDR - MTBDRplus]	511					0.0 (-4.5, +4.5)	0.0 (-0.9, +0.9)
KAN-R detection							
MTBDRsl	515	181	5	29	300	86 (81 to 90)	98 (96 to 99)
Xpert MTB/XDR	515	181	5	29	300	86 (81 to 90)	98 (96 to 99)
Diff. [Xpert MTB/XDR - MTBDRplus]	515					0.0 (-1.8, +1.8)	0.0 (-1.2, +1.2)
CAP-R detection							
MTBDRsl	513	53	1	34	425	61 (50 to 71)	100 (99 to 100)
Xpert MTB/XDR	513	53	1	34	425	61 (50 to 71)	100 (99 to 100)
Diff. [Xpert MTB/XDR - MTBDRplus]	513		1			0.0 (-4.2, +4.2)	0.0 (-0.9, +0.9)
AMV De amikacin recistant: CAD De capra						, , ,	, , ,

AMK-R: amikacin-resistant; CAP-R: capreomycin-resistant; CI: confidence interval; diff: difference; ETH-R: ethionamide-resistant; FN: false

negatives; FP: false positives; FQ-R: fluoroquinolone-resistant; INH-R: isoniazid-resistant; KAN-R: kanamycin-resistant; N: total number; TN:

540 true negatives; TP: true positives.

538

539


541

Presented data for line probe assays is from culture isolates of matched patients.

*Analysis is limited to patients with results on both Xpert MTB/XDR and the respective Hain line probe assay to provide a direct head-to-head comparison. An analysis comparing performance when testing for both Xpert MTB/XDR and LPA was done from culture isolates is available in Supplement S3.

Figures

Figure 1. Participant enrolment and exclusions.




AMK: amikacin; CAP: capreomycin; ETH: ethionamide; FQ: fluoroquinolones; INH: isoniazid; KAN: kanamycin; MTBC: *Mycobacterium tuberculosis* complex.

* Drug-resistant tuberculosis risk factors included: previously received >1 month of treatment for a prior tuberculosis episode (n=286); failing tuberculosis treatment as demonstrated by a positive sputum smear or culture after \geq 3 months of standard tuberculosis treatment (n=134); close contact with a known DR-TB case (n=59); newly diagnosed with MDR-TB within the last 30 days (n=305); or previously diagnosed with MDR-TB and failed tuberculosis treatment as demonstrated by a positive sputum smear or culture after \geq 3 months of a standard MDR-TB treatment regimen (n=103). Many patients reported more than one risk factor for drug-resistant tuberculosis.

† Culture-negative test results were observed in this study as the screening test (Xpert MTB/RIF or Ultra) was performed prior to enrolment on a different sputum sample than the sputum sample that was used for direct Xpert MTB/XDR and culture.

[‡] The sum for individual drugs does not correspond to 611 as some samples had no reference standard (phenotypic drug susceptibility testing and/or whole genome sequencing) result for certain drugs.

Figure 2. Sensitivity and specificity of the sputum-based Xpert MTB/XDR assay for resistance detection compared with a composite reference standard of phenotypic DST and WGS.



AMK: amikacin; CAP: capreomycin; ETH: ethionamide; FN: false negatives; FP: false positives; FQ: fluoroquinolones; INH: isoniazid; KAN: kanamycin; Sens: sensitivity; Spec: specificity; TN: true negatives; TP, true positives.


Figure 3. Sensitivity of the Xpert MTB/XDR assay for resistance detection by clinical site,

compared with a composite reference standard of phenotypic DST and WGS.

572

573

574



AMK: amikacin; CAP: capreomycin; ETH: ethionamide; FN: false negatives; FP: false positives; FQ: fluoroquinolones; INH: isoniazid; KAN: kanamycin; NITRD: National Institute of TB and Respiratory Diseases; PPI: Phthisiopneumology Institute; TN: true negatives; TP, true positives; WHC: Wits Health Consortium.

Note: Specificity was above 98% for all drugs and all sites.

Note: a table of Xpert MTB/XDR and reference standard discordant results is available in Supplement S3.